Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey

Published in Parkinson’s disease (2025)
Collaborator: Academics
Authors: Tangui Barré, Géraldine Cazorla, Vincent Di Beo, Fabienne Lopez, Lise Radoszycki, Gwenaëlle Maradan, Christelle Baunez, Patrizia Carrieri

People with Parkinson’s disease (PD) may use cannabis-based products for symptom management. In France, products containing tetrahydrocannabinol (THC) are prohibited, while cannabidiol (CBD)-products are readily available. However, data on cannabinoid use in French people with PD are lacking. To identify correlates of the use of cannabis-based products and to document their patterns of use and perceived effects.

Read the original article

Matthieu Morillon2025-06-17T17:24:28+02:00June 17th, 2025|Featured, Publications|

About the Author: Matthieu Morillon

As the Growth Marketing Director at Carenity, Matthieu leverages his expertise to generate leads for the RWE solutions while wholeheartedly supporting the growth of Carenity patient communities. With a wealth of diverse experiences and an innate drive for innovation, his insights naturally lend themselves to understanding and articulating the essential role of clinical trials in advancing medical research.

Patterns of Use and Patient-Reported Effects of Cannabinoids in People With PD: A Nationwide Survey

Share this on your social network !

About the Author: Matthieu Morillon